Literature DB >> 16001106

Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man.

Sargo Aalto1, Jouni Ihalainen, Jussi Hirvonen, Jaana Kajander, Harry Scheinin, Heikki Tanila, Kjell Någren, Harry Vilkman, Lars L Gustafsson, Erkka Syvälahti, Jarmo Hietala.   

Abstract

RATIONALE: The noncompetitive glutamate N-methyl-D: -aspartate receptor antagonist ketamine induces transient psychotic symptoms in man. Involvement of dopaminergic mechanisms in these effects has been suggested.
OBJECTIVES: The purpose of this article is to study the effects of ketamine on extrastriatal dopamine receptor availability in healthy subjects and extracellular dopamine levels in rat cortex.
MATERIALS AND METHODS: The effect of computer-driven subanesthetic ketamine infusion on cortical dopamine release was studied in healthy male subjects using a controlled study design. Dopamine D2/D3 receptor availability was quantified using positron emission tomography (PET) and [11C]FLB 457. A conventional region of interest-based analysis and voxel-based analysis was applied to the PET data. The ketamine-induced cortical dopamine release in rats was studied using in vivo microdialysis.
RESULTS: Ketamine infusion reduced significantly the [11C]FLB 457 binding potential (BP) in the posterior cingulate/retrosplenial cortices, suggestive of increased dopamine release. This brain imaging finding was further supported by a microdialysis experiment in rats showing that ketamine increased the extracellular dopamine concentration by up to 200% in the retrosplenial cortex. Ketamine-induced psychotic symptoms were associated with changes in the [11C]FLB 457 BP in the dorsolateral prefrontal and anterior cingulate cortices.
CONCLUSIONS: Our results suggest that cortical dopaminergic mechanisms have a role in the emergence of ketamine-induced psychosis-like symptoms in man. The glutamate-dopamine interaction in the posterior cingulate during ketamine infusion is well in line with the recent functional and structural imaging studies suggesting involvement of this cortical area in the development of schizophrenic psychosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16001106     DOI: 10.1007/s00213-005-0092-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  62 in total

Review 1.  Neurotransmitter interactions in schizophrenia--therapeutic implications.

Authors:  A Carlsson; N Waters; M L Carlsson
Journal:  Biol Psychiatry       Date:  1999-11-15       Impact factor: 13.382

Review 2.  Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers.

Authors:  M Slifstein; M Laruelle
Journal:  Nucl Med Biol       Date:  2001-07       Impact factor: 2.408

3.  Reproducibility of [11 C]FLB 457 binding in extrastriatal regions.

Authors:  Y Sudo; T Suhara; M Inoue; H Ito; K Suzuki; T Saijo; C Halldin; L Farde
Journal:  Nucl Med Commun       Date:  2001-11       Impact factor: 1.690

4.  Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D2 receptor.

Authors:  S Kapur; P Seeman
Journal:  Biol Psychiatry       Date:  2001-06-01       Impact factor: 13.382

5.  Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457.

Authors:  Sargo Aalto; Anna Brück; Matti Laine; Kjell Någren; Juha O Rinne
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

6.  MK-801 and ketamine induce heat shock protein HSP72 in injured neurons in posterior cingulate and retrosplenial cortex.

Authors:  F R Sharp; P Jasper; J Hall; L Noble; S M Sagar
Journal:  Ann Neurol       Date:  1991-12       Impact factor: 10.422

7.  Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex.

Authors:  N Lindefors; S Barati; W T O'Connor
Journal:  Brain Res       Date:  1997-06-13       Impact factor: 3.252

8.  Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers.

Authors:  A Breier; A K Malhotra; D A Pinals; N I Weisenfeld; D Pickar
Journal:  Am J Psychiatry       Date:  1997-06       Impact factor: 18.112

9.  Ketamine activates psychosis and alters limbic blood flow in schizophrenia.

Authors:  A C Lahti; H H Holcomb; D R Medoff; C A Tamminga
Journal:  Neuroreport       Date:  1995-04-19       Impact factor: 1.837

10.  Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine.

Authors:  B Adams; B Moghaddam
Journal:  J Neurosci       Date:  1998-07-15       Impact factor: 6.167

View more
  39 in total

Review 1.  Neurochemical modulators of sleep and anesthetic states.

Authors:  Christa J Van Dort; Helen A Baghdoyan; Ralph Lydic
Journal:  Int Anesthesiol Clin       Date:  2008

2.  Increased dopamine release in the right anterior cingulate cortex during the performance of a sorting task: a [11C]FLB 457 PET study.

Authors:  Ji Hyun Ko; Alain Ptito; Oury Monchi; Sang Soo Cho; Thilo Van Eimeren; Giovanna Pellecchia; Benedicte Ballanger; Pablo Rusjan; Sylvain Houle; Antonio P Strafella
Journal:  Neuroimage       Date:  2009-03-03       Impact factor: 6.556

3.  The effects of d-amphetamine on extrastriatal dopamine D2/D3 receptors: a randomized, double-blind, placebo-controlled PET study with [11C]FLB 457 in healthy subjects.

Authors:  Sargo Aalto; Jussi Hirvonen; Valtteri Kaasinen; Nora Hagelberg; Jaana Kajander; Kjell Någren; Timo Seppälä; Juha O Rinne; Harry Scheinin; Jarmo Hietala
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-05       Impact factor: 9.236

Review 4.  Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia.

Authors:  John E Lisman; Joseph T Coyle; Robert W Green; Daniel C Javitt; Francine M Benes; Stephan Heckers; Anthony A Grace
Journal:  Trends Neurosci       Date:  2008-04-07       Impact factor: 13.837

5.  Serum level of vascular endothelial growth factor decreased in chronic ketamine abusers.

Authors:  Ni Fan; Minling Zhang; Ke Xu; Xiaoyin Ke; Yi Ding; Daping Wang; Yuping Liu; Yuping Ning; Xuefeng Deng; Hongbo He
Journal:  Drug Alcohol Depend       Date:  2015-05-08       Impact factor: 4.492

6.  Do the dissociative side effects of ketamine mediate its antidepressant effects?

Authors:  David A Luckenbaugh; Mark J Niciu; Dawn F Ionescu; Neal M Nolan; Erica M Richards; Nancy E Brutsche; Sara Guevara; Carlos A Zarate
Journal:  J Affect Disord       Date:  2014-02-18       Impact factor: 4.839

7.  Differential modulation of ethanol-induced sedation and hypnosis by metabotropic glutamate receptor antagonists in C57BL/6J mice.

Authors:  Amanda C Sharko; Clyde W Hodge
Journal:  Alcohol Clin Exp Res       Date:  2007-12-07       Impact factor: 3.455

8.  Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study.

Authors:  Camilo de la Fuente-Sandoval; Pablo León-Ortiz; Mariana Azcárraga; Sylvana Stephano; Rafael Favila; Leonardo Díaz-Galvis; Patricia Alvarado-Alanis; Jesús Ramírez-Bermúdez; Ariel Graff-Guerrero
Journal:  JAMA Psychiatry       Date:  2013-10       Impact factor: 21.596

Review 9.  Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia.

Authors:  Daniel C Javitt; Stephen R Zukin; Uriel Heresco-Levy; Daniel Umbricht
Journal:  Schizophr Bull       Date:  2012-09       Impact factor: 9.306

10.  rTMS of the left dorsolateral prefrontal cortex modulates dopamine release in the ipsilateral anterior cingulate cortex and orbitofrontal cortex.

Authors:  Sang Soo Cho; Antonio P Strafella
Journal:  PLoS One       Date:  2009-08-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.